Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Drug combo tame high phosphorus in dialysis?

NCT ID NCT07776119

Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study looks at whether adding tenapanor to standard phosphate binders helps people on hemodialysis lower their blood phosphorus levels. High phosphorus is common in dialysis patients and can lead to bone and heart problems. The trial will follow about 200 adults who are already on phosphate binders but still have elevated phosphorus, measuring how many reach target levels and tracking safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tenapanor added to phosphate binders
What this could lead to
If effective, this combination could offer a new way to help dialysis patients manage high phosphorus levels, potentially reducing complications.
What could go wrong
This is a real-world study, not a controlled trial, so results may be influenced by patient differences. Tenapanor may cause gastrointestinal side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Hemodialysis patients with hyperphosphatemia despite the use of phosphate binders

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The subject has provided written informed consent prior to the initiation of any study-related activities. 2. Male or female subjects aged ≥18 years at the time of signing the informed consent form. 3. The subject is receiving regular maintenance hemodialysis (3 times per week, 4 hours per session) for at least 3 months. 4. The patient has been on phosphate binder therapy for at least 3 weeks, with a stable dose. 5. Serum phosphorus \> 4.5 mg/dL. Exclusion Criteria: 1. Hypersensitivity to Tenapanor or any excipients of the formulation. 2. History of diarrhea within 1 week prior to the start of treatment. Diarrhea is defined as a Bristol Stool Form Scale (BSFS) score ≥6 (i.e., mushy or liquid stools with no solid pieces), a daily bowel movement frequency ≥3 times, and a duration of ≥2 days. 3. Life expectancy \< 6 months. 4. Expected or planned kidney transplantation during the study period. 5. History of inflammatory bowel disease (IBD) or irritable bowel syndrome with diarrhea (IBS-D). 6. Any other condition that, in the opinion of the Investigator, makes the patient unsuitable for enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CKD 5D, hemodialysis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure hyperphosphatemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CKD 5D, hemodialysis Hyperphosphatemia undergoing hemodialysis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University People's Hospital

    Beijing, Beijing Municipality, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.